CLINICAL MEASURES OF BIOMARKER PERFORMANCE AND CARDIAC INFLAMMATION

Prepared by **Dr. Sidhartha Mullapudi**, DrNB (Cardiology), MD (General Medicine)
Last reviewed: October 2026

I CLINICAL MEASURES OF BIOMARKER PERFORMANCE (THE STATISTICAL FOUNDATION)

- **Core Evaluation Framework (Hlatky AHA Scientific Statement):** For a novel cardiovascular biomarker to demonstrate clinical utility beyond statistical association, it must be evaluated across three rigorous statistical domains: Discrimination, Calibration, and Reclassification.
- **Sensitivity and Specificity:** Sensitivity (True Positive Rate = TP / [TP + FN]) is the probability that the biomarker test is positive in patients who truly have the disease; high sensitivity is essential for rapid Rule-Out algorithms (such as the ESC 0/1-hour High-Sensitivity Cardiac Troponin pathway). Specificity (True Negative Rate = TN / [TN + FP]) is the probability that the test is negative in patients without the disease, essential for Rule-In confirmation.
- **Positive and Negative Predictive Values (PPV and NPV):** PPV is the probability that a patient with a positive biomarker truly has the disease, while NPV is the probability that a patient with a negative biomarker is truly disease-free. Unlike sensitivity and specificity (which are intrinsic test characteristics), PPV and NPV depend heavily on the pre-test prevalence of the disease in the target population.
- **Likelihood Ratios (LR+ and LR-):** Prevalence-independent metrics combining sensitivity and specificity: Positive Likelihood Ratio (LR+) = Sensitivity / (1 - Specificity) (values greater than 10 strongly rule in disease), and Negative Likelihood Ratio (LR-) = (1 - Sensitivity) / Specificity (values less than 0.1 strongly rule out disease).
- **Receiver Operating Characteristic (ROC) Curve and C-Statistic:** A graphical plot of Sensitivity (y-axis) versus 1 minus Specificity (False Positive Rate, x-axis) across all possible diagnostic cut-offs. Global discriminative ability is quantified by the Area Under the ROC Curve (AUC) or Harrell C-statistic: an AUC of 0.50 indicates no discrimination (chance alone), 0.70 to 0.79 indicates acceptable discrimination, and 0.80 or greater indicates excellent clinical discrimination.
- **Calibration (Hosmer-Lemeshow Goodness-of-Fit):** Measures how closely the biomarker model's predicted absolute risk matches the actual observed event rate across deciles of risk (a well-calibrated model yields a non-significant Hosmer-Lemeshow p-value greater than 0.05).

II ADVANCED RECLASSIFICATION METRICS

- **Limitation of the C-Statistic:** Because the C-statistic (AUC) is relatively insensitive to the addition of even strong independent predictors once baseline clinical variables (such as age, blood pressure, and lipids in the Framingham or SCORE2/PREVENT models) are included, reclassification metrics are required to prove incremental clinical value.
- **Net Reclassification Improvement (NRI):** Introduced by Pencina et al., the NRI quantifies the net proportion of individuals who are correctly moved upward or downward across clinically meaningful risk thresholds (e.g., low, intermediate, and high ASCVD risk) when the new biomarker is added to an established risk score:
  - **Events:** Correctly reclassifying patients who subsequently experience an event into a higher risk category increases the NRI.
  - **Non-Events:** Correctly reclassifying patients who remain event-free into a lower risk category also increases the NRI.
- **Integrated Discrimination Improvement (IDI):** Quantifies the continuous improvement in average sensitivity without sacrificing average specificity by measuring the increase in the separation of mean predicted probabilities between cases (events) and non-cases (non-events), independent of fixed risk category cut-offs.

Statistical Metric	Primary Question Answered	Key Exam Interpretation
AUC / C-Statistic (Discrimination)	Can the marker rank-order patients who will vs. will not have an event?	0.5 = coin flip; greater than 0.80 = strong discrimination; insensitive to single added markers
Hosmer-Lemeshow Test (Calibration)	Do predicted risk percentages match actual observed event rates?	Non-significant p-value (greater than 0.05) indicates good calibration
Net Reclassification Improvement (NRI)	Does the marker move patients across treatment thresholds into the right risk group?	Sum of net correct upward movement in cases + net correct downward movement in non-cases
Integrated Discrimination Improvement (IDI)	How much does the marker widen the probability gap between events and non-events?	Continuous measure of discrimination improvement; independent of arbitrary category cut-offs

III BIOMARKERS OF CARDIAC INFLAMMATION

- **High-Sensitivity C-Reactive Protein (hs-CRP):** Pentameric acute-phase reactant synthesized by hepatocytes under transcriptional control of Interleukin-6 (IL-6). It is the most validated inflammatory biomarker for atherosclerotic risk assessment (CDC/AHA risk strata: less than 1.0 mg/L = low risk; 1.0 to 3.0 mg/L = average/intermediate risk; greater than 3.0 mg/L = high vascular risk; values greater than 10 mg/L warrant repeat testing to exclude acute non-cardiovascular infection/inflammation).
- **Interleukin-6 (IL-6) and Interleukin-1 Beta (IL-1b):** NLRP3 inflammasome activation within cholesterol crystal-laden macrophages cleaves pro-IL-1b into active IL-1b, which drives upstream IL-6 production and downstream hepatic CRP and fibrinogen synthesis—forming the central canonical inflammatory pathway of atherothrombosis.
- **Myeloperoxidase (MPO):** A heme-containing enzyme secreted by activated neutrophils and monocytes during plaque destabilization and neutrophil extracellular trap (NET) formation. MPO generates hypochlorous acid and reactive oxidants, oxidizes LDL, consumes endothelial nitric oxide, and activates matrix metalloproteinases; elevated levels predict short-term MACE in acute chest pain cohorts independent of troponin.
- **Soluble ST2 (sST2):** Circulating soluble isoform of the Interleukin-1 receptor-like 1 (IL1RL1) protein. Transmembrane ST2 (ST2L) binds Interleukin-33 (IL-33) to exert antihypertrophic, antifibrotic cardioprotection; sST2 acts as a circulating decoy receptor that sequesters IL-33, promoting myocardial fibrosis and adverse remodeling. Because sST2 has low biological variability and is minimally affected by age, BMI, or renal impairment, it is a powerful prognostic marker in acute and chronic Heart Failure.
- **Galectin-3:** A beta-galactoside-binding lectin secreted by activated cardiac macrophages that stimulates myofibroblast proliferation and collagen Type I synthesis, serving as a direct biomarker of myocardial fibrosis and adverse prognosis in HFrEF and HFpEF (Class IIb in the 2017 ACC/AHA/HFSA heart failure guideline update, alongside sST2, for additive risk stratification).

IV LANDMARK TRIALS TARGETING CARDIAC INFLAMMATION

- **JUPITER Trial (2008):** Randomized 17,802 primary-prevention individuals with LDL-C less than 130 mg/dL but elevated hs-CRP of 2.0 mg/L or greater to Rosuvastatin 20 mg versus placebo; stopped early after demonstrating a 44 percent relative risk reduction in the primary MACE endpoint, proving that statins reduce events in patients with heightened inflammatory risk even when LDL-C is not elevated.
- **CANTOS Trial (2017):** Randomized 10,061 patients with prior myocardial infarction and persistent residual inflammatory risk (hs-CRP of 2.0 mg/L or greater) to Canakinumab (anti-IL-1b monoclonal antibody) versus placebo. The 150 mg dose reduced recurrent MACE by 15 percent without altering LDL-C or ApoB (with a 25 percent MACE reduction in "on-treatment responders" achieving hs-CRP less than 2 mg/L), providing definitive proof of the inflammatory hypothesis of atherothrombosis, though accompanied by a higher incidence of fatal infection.
- **Colchicine Coronary Trials (COLCOT 2019, LoDoCo2 2020, and CLEAR SYNERGY 2024):** COLCOT (post-MI within 30 days) and LoDoCo2 (chronic coronary syndrome) demonstrated 23 percent and 31 percent reductions in MACE with low-dose Colchicine (0.5 mg daily), earning a Class IIa recommendation in the 2024 ESC Chronic Coronary Syndromes Guidelines. However, the larger CLEAR SYNERGY (OASIS-9) Trial (NEJM 2024, n = 7,062) in acute MI treated with PCI showed no reduction in MACE at 3 years despite lowering CRP, tempering routine acute post-MI initiation while supporting selective use in chronic residual inflammatory risk.

V PRACTICAL CONSIDERATIONS IN THE INDIAN CLINICAL CONTEXT

- **Elevated Baseline Inflammatory Phenotype:** Due to high rates of visceral adiposity ("thin-fat" South Asian phenotype), insulin resistance, and atherogenic dyslipidemia, Indian patients frequently exhibit higher baseline hs-CRP levels, using hs-CRP greater than 2.0 mg/L as a practical risk enhancer to guide aggressive statin intensification in borderline/intermediate primary prevention.
- **Pragmatic Anti-Inflammatory Therapy:** Because targeted anti-cytokine biologics (such as canakinumab) are unavailable or cost-prohibitive for cardiovascular indications, high-intensity statins combined with low-dose Colchicine (0.5 mg once daily) represent the primary accessible strategy for patients with recurrent atherosclerotic events and persistent hs-CRP elevation (greater than 2 mg/L) despite optimal LDL-C control (less than 55 mg/dL) and normal renal function.
- **sST2 Utility in Comorbid Heart Failure:** While NT-proBNP remains the Class I diagnostic and prognostic standard for heart failure, sST2 offers complementary prognostic utility in Indian tertiary centers because its concentration is not falsely suppressed by obesity or confounded by chronic kidney disease.

KEY REFERENCES

- **Hlatky MA, Greenland P, Arnett DK, et al.:** Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association, *Circulation*, 2009.
- **Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS:** Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond, *Statistics in Medicine*, 2008.
- **Ridker PM, Everett BM, Thuren T, et al. (CANTOS Trial Group):** Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease, *New England Journal of Medicine*, 2017.
- **Jolly SS, d'Entremont MA, Lee SF, et al. (CLEAR SYNERGY OASIS 9 Investigators):** Colchicine in Acute Myocardial Infarction, *New England Journal of Medicine*, 2024.